When compared with placebo or other therapies, GLP-1 agonists were associated with an increased risk of biliary disease [23]: Overall biliary disease: RR 1.37(95% CI 1.231.52) Cholelithiasis: RR 1.27 (95% CI 1.101.47) Cholecystitis: RR 1.36 (95% CI 1.141.62) Mechanisms: Reduced gallbladder motility Rapid weight loss increased cholesterol saturation and gallstone formation
While drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have proven to be game-changers for weight loss and metabolic health, many users report an unexpected side effect: restless, low-quality sleep
This new class of drugs are an example of medical science at its best a way for people to achieve dramatic results and, in doing so, have a chance at a much higher quality of life, says Lifeforce Co-Founder Dugal Bain-Kim
Q: How many sessions are included
Reduce caffeine after early afternoon
This suggests that continued treatment might produce additional weight loss beyond what was measured